The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Immune profiling of BM microenvironment to identify predictors of disease progression in myeloma
In this discussion, Chaitanya Acharya, PhD, and George Mulligan, PhD, Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, discuss their work with Immune Atlas, an extension of the longitudinal CoMMpass study (NCT0145429), which analyzes tumor genomics and immune composition in patients with newly diagnosed multiple myeloma (NDMM). They explain how immune profiling of the bone marrow (BM) microenvironment differentiates patients with rapid disease progression from those with longer disease-free intervals, noting that progressors show unique differences, particularly involving dysfunctional CD8+ T-cells and inflammatory monocytes. This study reveals potential immune-based predictors of disease progression and complements traditional cytogenetic risk factors. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
